Shenzhen Magicrna Biotechnology Co., Ltd
Clinical trials sponsored by Shenzhen Magicrna Biotechnology Co., Ltd, explained in plain language.
-
New CAR-T therapy aims to tame lupus and scleroderma
Disease control Not yet recruitingThis early-stage study tests a new treatment called HN2302 in 12 adults with autoimmune diseases like lupus or scleroderma. The therapy uses the body's own immune cells, modified to target and reduce harmful immune activity. The main goal is to check safety, while also seeing if …
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 06:47 UTC
-
New cell therapy trial aims to tame muscle weakness in rare disease
Disease control Not yet recruitingThis early study tests a new treatment called HN2301 in 6 adults with generalized myasthenia gravis, a disease that causes muscle weakness. The treatment uses modified immune cells (CAR-T cells) to target and reduce harmful antibodies. The main goal is to check safety and see how…
Phase: PHASE1 • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated May 22, 2026 13:51 UTC